miPCancer develops a cancer discovery platform that identifies novel therapeutic targets and accelerates the pre-clinical development of new cancer treatments. Their platform leverages advanced genomic and proteomic analysis to uncover unique cancer vulnerabilities, enabling the creation of targeted therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional drug development has shown limited success in creating curative treatments for aggressive and treatment-resistant cancers, especially those with systemic spreading. A significant challenge lies in targeting transcription factors, which are often unstructured proteins with complex interaction networks, making them difficult to inhibit with traditional methods. This creates a need for novel strategies to identify and refine inhibitors for these challenging targets to reduce cancer mortality.
Solution
Pioneer Research is developing the miPCancer Discovery and Development Platform to identify and develop inhibitors of challenging cancer drivers, particularly focusing on microproteins. Microproteins, naturally occurring small inhibitors and activators of larger proteins, are often overlooked by standard genome discovery algorithms. The platform employs a target-centric, activity-based cellular approach to identify microprotein inhibitors of challenging drug targets. These inhibitors are then refined through optimized activity and cellular assays to improve biological effects, binding kinetics, and stability. The company has proof-of-concept evidence for the potent inhibition of cancer-driving transcription factors under pre-clinical development.
Target Audience
The primary audience includes biopharmaceutical companies and academic researchers focused on cancer drug discovery and development, particularly those working on treatment-resistant cancers and challenging drug targets.
Features
- Proprietary miPCancer Discovery and Development Platform for identifying microprotein inhibitors.
- Target-centric, activity-based cellular screening approach.
- Focus on challenging drug targets, including unstructured transcription factors.
- Microprotein-based tools that act as natural inhibitors of larger proteins.
- Optimized activity and cellular assays to refine inhibitors.
- Pre-clinical development of inhibitors in 3D cellular and animal models.
- Expression-validated microprotein screening platform.